A carregar...
Vorinostat Downregulates CD30 and Decreases Brentuximab Vedotin Efficacy in Human Lymphocytes
With an increasing number of clinical trials looking at combination therapies in cancer, potential drug-drug interactions require particular attention. One such instance is the treatment of CD30(+) tumors after previous vorinostat (SAHA) failure with the anti-CD30 antibody-drug conjugate brentuximab...
Na minha lista:
| Publicado no: | Mol Cancer Ther |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4258453/ https://ncbi.nlm.nih.gov/pubmed/25319394 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0593 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|